Advanced Cell Technology Announces 2012 First Quarter Results
MARLBOROUGH, Mass., May 08, 2012 (BUSINESS WIRE) -- Advanced Cell Technology,
Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine,
announced today first quarter financial results for the period ended March 31,
2012. The Company reported a loss from operations of $(5.4) million compared to a
loss from operations of $(4.8) million in the 2011 first quarter. ACT reported a
net loss of $(5.7) million or $(0.00) per share, compared to a loss in the same
period in 2011 of $(3.3) million, or $(0.00) per share.
Net cash used in operations for the 2011 first quarter was $4.8 million, compared
to net cash used in operations of $3.4 million in the same period in 2011. The
Company ended the 2012 first quarter with cash and cash equivalents of $10.8
million, compared to $13.1 million as of December 31, 2011.
Highlights from the first quarter of 2012 included:
-- IRB approval from Wills Eye Institute in Philadelphia, one of the nation's top
ophthalmology centers, to treat macular degeneration.
-- Initiated Europe's first human Embryonic Stem Cell transplant at Moorfields
Eye Hospital
-- Published first report of human Embryonic Stem Cell (hESC)-derived cells
transplanted into patients to treat macular degeneration in leading medical
journal, The Lancet.
-- Dosed additional patients in the company's clinical trial treating Stargardt's
Disease.
-- Added Aberdeen Royal Infirmary in Scotland as site for Phase I/II Clinical
Trial using hESC-derived RPE cells for macular degeneration.
"We are very pleased with our progress in the clinic so far," said Chairman and
CEO Gary Rabin. "We are encouraged by the results we have seen from the early
patients treated in each of our indications, and look forward to completing the
trials on schedule."
Conference call and Webcast
The Company will hold a conference call tomorrow at 9 a.m. eastern time to
discuss the first quarter results and business outlook. Interested parties may
access the call live by dialing (888) 264-3177 and using conference ID 72827188.
This event will be streamed via webcast. The webcast will be available at
us.meeting-stream.com. A replay of the call
will also be available via the same link.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc., is a biotechnology company applying cellular
technology in the field of regenerative medicine. For more information, visit
advancedcell.com.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results,
future growth in research and development programs, potential applications of our
technology, opportunities for the company and any other statements about the
future expectations, beliefs, goals, plans, or prospects expressed by management
constitute forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Any statements that are not statements
of historical fact (including statements containing the words "will," "believes,"
"plans," "anticipates," "expects," "estimates," and similar expressions) should
also be considered to be forward-looking statements. There are a number of
important factors that could cause actual results or events to differ materially
from those indicated by such forward-looking statements, including: limited
operating history, need for future capital, risks inherent in the development and
commercialization of potential products, protection of our intellectual property,
and economic conditions generally. Additional information on potential factors
that could affect our results and other risks and uncertainties are detailed from
time to time in the company's periodic reports, including the report on Form 10-K
for the year ended December 31, 2011. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company's management at the time they
are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. Forward-looking statements are based on the beliefs,
opinions, and expectations of the company's management at the time they are made,
and the company does not assume any obligation to update its forward-looking
statements if those beliefs, opinions, expectations, or other circumstances
should change. There can be no assurance that the Company's clinical trials will
be successful.
SOURCE: Advanced Cell Technology, Inc.
CEOcast, Inc.
Investors:
James Young, 212-732-4300
or
Press:
ACT Corporate Communications
Bill Douglass, 646-450-3615
or
Russo Partners
Martina Schwarzkopf, Ph.D., 212-845-4292
or
Business Development:
ACT
Matthew Vincent, Ph.D., 508-756-1212 x324
mvincent@advancedcell.com |
